← Back to Screener
Gossamer Bio, Inc. Common Stock (GOSS)
Price$0.17
Value ScoreB
Growth ScoreC
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-102.69%
Price vs S&P 500 (4W)-46.47%
VGM Score42.15
Market Capitalization$41.07M
All Metrics
Book Value / Share (Quarterly)$0.13
P/TBV (Annual)14.41x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.73
Price vs S&P 500 (YTD)-102.51%
Net Profit Margin (TTM)-324.82%
EPS (TTM)$-0.78
10-Day Avg Trading Volume13.31M
EPS Excl Extra (TTM)$-0.78
EPS (Annual)$-0.75
ROI (Annual)-24.90%
Cash / Share (Quarterly)$0.42
Revenue Growth QoQ (YoY)71.45%
ROA (Last FY)-98.91%
Revenue Growth TTM (YoY)-55.42%
EBITD / Share (TTM)$-0.78
ROE (5Y Avg)-528.46%
Operating Margin (TTM)-321.92%
Cash Flow / Share (Annual)$-0.73
P/B Ratio1.42x
P/B Ratio (Quarterly)7.07x
Net Income / Employee (Annual)$-1,058,200
EV / Revenue (TTM)3.58x
Net Interest Coverage (TTM)-17.90x
ROA (TTM)-96.10%
EPS Incl Extra (Annual)$-0.75
Current Ratio (Annual)2.64x
Quick Ratio (Quarterly)1.92x
3-Month Avg Trading Volume14.85M
52-Week Price Return-86.11%
Revenue / Employee (TTM)$345,000
Tangible BV / Share (Quarterly)$0.46
P/S Ratio (Annual)0.85x
Asset Turnover (Annual)0.28x
52-Week High$3.87
EPS Excl Extra (Annual)$-0.75
CapEx CAGR (5Y)-44.50%
26-Week Price Return-94.76%
Quick Ratio (Annual)2.35x
13-Week Price Return-66.48%
Total Debt / Equity (Annual)6.70x
Current Ratio (Quarterly)2.20x
Enterprise Value$198.81M
Asset Turnover (TTM)0.30x
Book Value / Share Growth (5Y)-53.08%
Revenue / Employee (Annual)$301,100
Pretax Margin (Annual)-351.67%
Cash / Share (Annual)$0.59
3-Month Return Std Dev126.29%
Net Income / Employee (TTM)$-1,120,500
ROE (Last FY)-191.67%
Net Interest Coverage (Annual)-19.13x
EPS Basic Excl Extra (Annual)$-0.75
Receivables Turnover (TTM)7.01x
Total Debt / Equity (Quarterly)6.83x
EPS Incl Extra (TTM)$-0.78
ROI (TTM)-23.00%
P/S Ratio (TTM)0.74x
Revenue / Share (Annual)$0.21
Tangible BV / Share (Annual)$0.13
Price vs S&P 500 (52W)-110.48%
Year-to-Date Return-94.35%
5-Day Price Return-11.66%
EPS Normalized (Annual)$-0.75
ROA (5Y Avg)-65.35%
Net Profit Margin (Annual)-351.49%
Month-to-Date Return-24.21%
Cash Flow / Share (TTM)$-1.55
EBITD / Share (Annual)$-0.75
Operating Margin (Annual)-352.23%
LT Debt / Equity (Annual)6.70x
ROI (5Y Avg)-63.48%
LT Debt / Equity (Quarterly)6.81x
EPS Basic Excl Extra (TTM)$-0.78
P/TBV (Quarterly)1.66x
P/B Ratio (Annual)6.95x
Pretax Margin (TTM)-324.98%
Book Value / Share (Annual)$0.13
Price vs S&P 500 (13W)-74.73%
Beta2.06x
P/FCF (Annual)2053.59x
Revenue / Share (TTM)$0.24
ROE (TTM)-118.77%
52-Week Low$0.16
vGradeB
gGradeC
mGradeF
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.20est. -0.17
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.19
3.73
3.75
3.69
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GOSSGossamer Bio, Inc. Common Stock | B | C | F | $0.17 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Gossamer Bio is a clinical-stage biopharmaceutical company developing therapeutics in immunology, inflammation, and oncology. Its pipeline includes Seralutinib for pulmonary arterial hypertension, GB004 for inflammatory bowel disease, GB1275 for oncology indications, and GB001 for eosinophilic asthma.